[
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "For an all-or-nothing vaccine, will the 1-incidence rate ratio overestimate / underestimate / correctly estimate the per-exposure vaccine efficacy?\n\nAnswer Choices:\nA. overestimate\nB. underestimate\nC. correctly estimate\nD. /\nE. /"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762208799-vZMtaj157begjfFLci3o",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"A. Overestimate. For an all-or-nothing vaccine a fraction p is fully protected and contributes person-time without events, which reduces the observed incidence rate in the vaccinated arm more than the per-exposure susceptibility reduction p. Thus 1 \u2212 (incidence rate ratio) will tend to be larger than the true per-exposure vaccine efficacy. (Simple numeric examples show 1\u2212IRR > p.)\",\"answer_letter\":\"A\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Recalling vaccine efficacy definitions**\n\nI need to remember the definitions of vaccine efficacy. For all-or-nothing vaccines, they either fully protect a fraction of vaccinated individuals or not at all, leaving the unprotected with the same risk as the unvaccinated. The per-exposure vaccine efficacy seems to be defined as 1 minus the relative risk of infection for vaccinated versus unvaccinated individuals per exposure. I\u2019m trying to reason through how the incidence rate ratio in trials could lead to bias due to depletion of susceptibles.**Understanding per-exposure vaccine efficacy**\n\nI\u2019m working out that the per-exposure vaccine efficacy (VE) equals p, where p represents the fraction of individuals protected. In trials, they measure the incidence rate ratio over a follow-up period. Given that some vaccinated individuals are fully protected while others aren't, this can influence the incidence ratio. There may be issues related to the depletion of susceptibles, leading to potential bias in the calculations. After considering this, it seems that 1 minus the incidence rate ratio accurately estimates the per-exposure VE.**Examining vaccine efficacy over time**\n\nI need to be cautious about how vaccine efficacy might decrease or affect measurements over a long period. If there's an \"all-or-nothing\" effect, the susceptible proportion in the unvaccinated group could diminish faster than in the vaccinated group over time. When calculating the rates, I see that the vaccinated group has a fraction p that is protected and a (1-p) fraction that remains susceptible. \n\nThe overall hazard for the vaccinated group evolves over time, and this requires careful consideration of the incidence rate and person-time at risk, especially for those already infected.**Analyzing incidence rates in unvaccinated groups**\n\nI'm considering the hazard constant \u03bb for susceptible individuals, particularly in the unvaccinated group where the susceptible fraction starts at 1 and declines as infections occur. However, I must remember that individuals are excluded from the risk set once they become infected. The incidence rate during follow-up is \u03bb for those still susceptible. \n\nI need to ensure that when I calculate rates for the vaccinated group, I'm only counting individuals still at risk. Ultimately, the incidence rate depends on the proportion of susceptible individuals over time.**Calculating incidence rates in vaccinated groups**\n\nI'm trying to evaluate how the incidence rate reflects the events over person-time for both unvaccinated and vaccinated groups. For unvaccinated individuals, the expected incidence rate works out to \u03bb, while for vaccinated individuals, the incidence rate is impacted by the protected fraction, which contributes zero events. This means the overall ratio is likely to underestimate the true per-exposure vaccine efficacy. I need to ensure I explain this clearly, focusing on how protected individuals inflate person-time without contributing to event counts, leading to bias in the results.",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Recalling vaccine efficacy definitions**\n\nI need to remember the definitions of vaccine efficacy. For all-or-nothing vaccines, they either fully protect a fraction of vaccinated individuals or not at all, leaving the unprotected with the same risk as the unvaccinated. The per-exposure vaccine efficacy seems to be defined as 1 minus the relative risk of infection for vaccinated versus unvaccinated individuals per exposure. I\u2019m trying to reason through how the incidence rate ratio in trials could lead to bias due to depletion of susceptibles.**Understanding per-exposure vaccine efficacy**\n\nI\u2019m working out that the per-exposure vaccine efficacy (VE) equals p, where p represents the fraction of individuals protected. In trials, they measure the incidence rate ratio over a follow-up period. Given that some vaccinated individuals are fully protected while others aren't, this can influence the incidence ratio. There may be issues related to the depletion of susceptibles, leading to potential bias in the calculations. After considering this, it seems that 1 minus the incidence rate ratio accurately estimates the per-exposure VE.**Examining vaccine efficacy over time**\n\nI need to be cautious about how vaccine efficacy might decrease or affect measurements over a long period. If there's an \"all-or-nothing\" effect, the susceptible proportion in the unvaccinated group could diminish faster than in the vaccinated group over time. When calculating the rates, I see that the vaccinated group has a fraction p that is protected and a (1-p) fraction that remains susceptible. \n\nThe overall hazard for the vaccinated group evolves over time, and this requires careful consideration of the incidence rate and person-time at risk, especially for those already infected.**Analyzing incidence rates in unvaccinated groups**\n\nI'm considering the hazard constant \u03bb for susceptible individuals, particularly in the unvaccinated group where the susceptible fraction starts at 1 and declines as infections occur. However, I must remember that individuals are excluded from the risk set once they become infected. The incidence rate during follow-up is \u03bb for those still susceptible. \n\nI need to ensure that when I calculate rates for the vaccinated group, I'm only counting individuals still at risk. Ultimately, the incidence rate depends on the proportion of susceptible individuals over time.**Calculating incidence rates in vaccinated groups**\n\nI'm trying to evaluate how the incidence rate reflects the events over person-time for both unvaccinated and vaccinated groups. For unvaccinated individuals, the expected incidence rate works out to \u03bb, while for vaccinated individuals, the incidence rate is impacted by the protected fraction, which contributes zero events. This means the overall ratio is likely to underestimate the true per-exposure vaccine efficacy. I need to ensure I explain this clearly, focusing on how protected individuals inflate person-time without contributing to event counts, leading to bias in the results.",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "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",
                "id": "rs_0ab55bc679400be50169092c1fd97081939231209acd65132a",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762208799,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 1764,
        "prompt_tokens": 101,
        "total_tokens": 1865,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 1664,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.00355325,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 2.525e-05,
          "upstream_inference_completions_cost": 0.003528
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "For an all-or-nothing vaccine, will the 1-incidence rate ratio overestimate / underestimate / correctly estimate the per-exposure vaccine efficacy?\n\nAnswer Choices:\nA. overestimate\nB. underestimate\nC. correctly estimate\nD. /\nE. /"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762208799-dCQqSpUwWpKH2KYHy8cX",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"C\\n\\nExplanation: An all-or-nothing vaccine fully protects a fraction p of vaccinees and leaves the rest fully susceptible. The incidence among vaccinated = (1\u2212p)\u00d7incidence in controls, so IRR = 1\u2212p and 1\u2212IRR = p, which equals the per-exposure vaccine efficacy.\",\"answer_letter\":\"C\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Interpreting vaccine efficacy questions**\n\nI need to clarify the question about whether the 1-incidence rate ratio (IRR) overestimates, underestimates, or correctly estimates the per-exposure vaccine efficacy for an all-or-nothing vaccine. This type of vaccine provides full protection to a fraction of the population (p), while others remain susceptible. The per-exposure vaccine efficacy is often defined as 1 minus the relative risk of infection upon exposure. For all-or-nothing, per-exposure efficacy equals p since protected individuals have zero risk. The IRR is based on incidence in vaccinated versus unvaccinated individuals.**Estimating vaccine efficacy**\n\nFor an all-or-nothing vaccine, the vaccinated group includes a fraction (p) that is fully protected with zero incidence, and a fraction (1-p) that has the same infection rate as the unvaccinated. This means the incidence in the vaccinated equals (1-p) times the incidence in the unvaccinated. Consequently, the incidence rate ratio (IRR) becomes (1-p), leading to 1 - IRR equaling p, which measures per-exposure vaccine efficacy. \n\nThus, 1 - IRR correctly estimates this efficacy. I'll format the answer in JSON as specified.",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Interpreting vaccine efficacy questions**\n\nI need to clarify the question about whether the 1-incidence rate ratio (IRR) overestimates, underestimates, or correctly estimates the per-exposure vaccine efficacy for an all-or-nothing vaccine. This type of vaccine provides full protection to a fraction of the population (p), while others remain susceptible. The per-exposure vaccine efficacy is often defined as 1 minus the relative risk of infection upon exposure. For all-or-nothing, per-exposure efficacy equals p since protected individuals have zero risk. The IRR is based on incidence in vaccinated versus unvaccinated individuals.**Estimating vaccine efficacy**\n\nFor an all-or-nothing vaccine, the vaccinated group includes a fraction (p) that is fully protected with zero incidence, and a fraction (1-p) that has the same infection rate as the unvaccinated. This means the incidence in the vaccinated equals (1-p) times the incidence in the unvaccinated. Consequently, the incidence rate ratio (IRR) becomes (1-p), leading to 1 - IRR equaling p, which measures per-exposure vaccine efficacy. \n\nThus, 1 - IRR correctly estimates this efficacy. I'll format the answer in JSON as specified.",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCSwtl8G1MmjYc3A4dXNG1qg5hRhdN0AdW3tkXZ6-9doNCmTfKDidG2Gzoi_uiKWqPEV_jEK-lDvc3L2QryeLZSIo2KZog_3eQHG7L9uAbeO2pQhHDsrj_587eHAgv0eLNxVRr7CE0KQlwMwyl_njOe6KKMzoaUS4o0pOYO-g9eAjIh9Kc85l-suM2-U2F3dow_NyCGNA78vmfAQnunSLPHYkgCkSuatl7kY_fG3yHM6wkQQ-OiP61xbiJTJds6GkfODdHQj8o-A5DXOC2-sD7f7sKzmgdNgO74eew1_4vT_F3EGZOd287N4a2bmmnnC6vuAlWx2oSk0XfBB7Kl838d91xQOcUUWDLEGnjOYYOHchUSSc2ZniVMg15TPl5pV03mSLW_FkOYfDXk2UgAlOv7NbODrRwmzF7GsPECFMYSVmlqud5vZtI3xel2MSUwZJxAlfARMszfupG5K0MtJm7iYGlBl-TtE8cDuFUXMRivfc_LdIet0gNKGIWVpo87psIGdqISwDwiruAezWETveoGqW7mp-HSRfaryTIFPahIHul-jMR6s1Zrp7pGLc9Cpi3l-3CozfAIda-UXaTOdWGOwhUC20JOOiA6kuHF7cdYdbYTB4igbxz1WdSOFdd_gUWNJwTvI-6GApXRz3AQ86T_CsXZu1w7mew_iq2JpcjvlvlBzcoGBGSM9PBrPazfF-DEB5S8ME7HlQ5zGgJy6xIuM-chHht17xnlAu3wWXO9Kkvm2gVdIHBrZIG7NsA8ugmOzy1PMZ2hVWuhJICTNjwpLnwRzouudRluqdGUpArjDplHA7PeYALle2f0qr-cyAUpsGk6F10Pf-thO9B7MRkZpQzeMxu_tzkyfhLOKwVzsIvTGsn0-kI9I1ED7Zwxr0jRv8KxW0fw-Ntc4zxCpZLPKXQuI40en6hYx0wfdtUOjx4mV5Fd5ydl64LDShO8C2lm67wQ8WJzbY2jskG12FuUg6r-fUfd18hCJteZ_ZNCDMlSgyx_KrOZ0KKuiGnMqZ5w3QJQv407hZ-u0OodL0xQKCahgg9zVaTEzZLxvmKcQVHNW9XvWCgj2DchPtOa2MewHtV2MIRENDhFezcnBYMpDd1MDHrc4BuOLvHOvVTro5-tF8AyDJJKQe7ZLpqzqReCPgbPmg5dgseNDq4Sz7qt7y1nFgp8u4608MqWqTduag2k6SKghbDfWrnxabea-MSCFZJRX_LhZc5GrhZWIedR4pCGPeh-zBjITQu95L6vvFVAH25Kp82r5KeFy1b3e-Mbemf1NRHFTRvOB5nmG6jyMBspQe-774nLrcNagAZcCxHmYgr4ESZvI4iVvsF3soLrFh373KSMBvda30Uh4Si7lSh0efxMdZgzGjPiHcicLRDaWQpv4DdzGHmIVFfshE9wkcPdP5-mEKU0oCfHsRVFQg_uS6ovTnxfVQcadC3Y-EjXD-NW4wLAY8HcuxsHA0eUG0iciN-wcBBSyA_Lv-okHl2qFsmNI201JP9D3MMT3IH7bwqTBpI4LuVaptW5uVvjXm0cEBOO_4LEY_qY_z49yREO-cqRWNIqbbffxx0zCdTzN-8muVoJPL12yR3uo1_90DJsd4th0QyZzkRb8NDlG02MD7o4nmhpn8Jf03wduWQ5nKlDTU0xbDxER71lygOZFXRTO56RboPzdwBc8ep7E7Ver9NRzVvzeVAg9dChJ-CS3l93D37m3rSBiSQPEWNaNiU_qNywB7ey47sbRU-D0rFCrSWo5y19q1r_CpN1DMsRuV7VSlLnedItLgxK11ST3OHGpdfF7G6NBphubb26wDNDHsVR1ZavazNBXO-wSnOS9Z8nbGAX1L1WdS6Cag83W93XqIgKGlTiaxe5Vam9e0IinYkygVjhnKIahlEkZ5qsT99HGXaaAeFll-OxSHJRmig-vUikp8tF-34uzMs5iNl4KZDImArL1OTl0_MZ1LYDyVD4moQKeGyC6bZc47gJYUWgkTmCeNGO_MG6QlHnOMseztcwba--l1_dgoY1Wu6R3VV4O9pvu1XEkLSgmA6VbXCq2wGuvDud-QgVm7l1_zHuikDS5TPzzll0i-M-myPt_n-HNrsXAlBapyn-kN4LeFukvLdwQGLnaYnEfMP77cTl5SE2xQ4rmY5YG6W_MvygS6bo9GyVvxFyv7g5-tiIkGX7f8Fnq8_QIWSZG2pcxR_6sTCKns1L6lHqNfI2dMkAMH5D4f3aFiyPWP3xsi4idjJ54h6hqszvpcEusY08twdqld_bs1JdwWCOFwOl5SiEFr-l_aZRsqgkKIz7CR-NnBm1jOoawQ2PlYB77Jfv6OGTFPF7PF91gGiiVGR_knGB0AcCNxHdTWQEpPOFrwT_q-vCykI6arrb95m5c9rYZ85YS_ULosHvUPTtzygvZNQO1efhTdMMAGDAKbYPsENKhDW4RJJQg41rdpy3TYZ4CmIGB_yfnXcBRfra-eiszzxIZzYzTwq_xYeF9G-M-jquLjC91CxV7nAmikvyu1e3rH81dONj4R-0Juua7QWoHAMB5T_XSKKga_3_sNdKBrJl0YpMJmDx3ANhBGlsNE4hu_oU7iGtjoR9OeeQCLjiQvBBkxztAyeSq9bnGPQuPuEh9x6rvduwArHY-FRqeq3EnSofZ0QFVrpkJc3ufOHuDm3a0EvjlJNWlz78dWmWBhQrttWnv09_mxQNbnQft20MT2M2rmjJGXGYRQeNtQJ22CXN62yPJJP65tww2QDnooogpF91if1joFR7ylhrF6HKxdEjVQDpX2vkUf3uQ4tbznvGViDBHUkbaCrY6tKA0GDAdYJqGyf_wuS_3J1twdmlUCiGXXObgt0okFIhPx-xnVrfU9LD1kPQn8Dvb9IfOLzwGojSHWUn_YYd3w8k3lg1SX45HlZX2GzTm3QihdBqEyk4dUsXcjMz91Du7wWWA8Df4zOUh2y6RmGW43-ufslgM0ZlFGJNghuRvPbY2MvIeHozLVT114neozLOehR4CrtjBRWXyvblhVcch07H9V4A1HhEJ8BHSv4TYcqNOGT5Ji0XDEc7JjSJyarazRFRJg0QWdhpLsMMs9bogFuF8p-Yp--A6Zcgix1Qh0i2CVUDiFgVFzNUgCiSPKkZgeLfPMYOosZ-qDUZQaNhDvDvNPaLJ2jqzRImOC-OT5r85ZtP6b9P7ldQ52YVfseClib78pB-E5ryyzooEQXMF8MOwLaP9VMQYvo7_pdq1ewp3WBApuTAFtdrOnhob3thzxSfpfylZPCStQ0LCQwFP00B6qGXZLyvCc23y8_uslce3VSlQIZaJY1PvQ7jDwRsjRKE9MY3virBC7CPYBemPV0DRTHndlvGJyegoW2SWvossLzaQuqmGrNSiD8-5ZkSmvNF6-2M3m8HlvWsw7loFMuh22JKlfrKNovU29yqay7I-peJjq-Gur8d20W4PzbpJGiemehaZSZApMQSM4JFI4o3-Lk8dQHw==",
                "id": "rs_0ec75231b990277a0169092c200b5881969135b0b6f92e9160",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762208799,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 469,
        "prompt_tokens": 101,
        "total_tokens": 570,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 384,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.00096325,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 2.525e-05,
          "upstream_inference_completions_cost": 0.000938
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "For an all-or-nothing vaccine, will the 1-incidence rate ratio overestimate / underestimate / correctly estimate the per-exposure vaccine efficacy?\n\nAnswer Choices:\nA. overestimate\nB. underestimate\nC. correctly estimate\nD. /\nE. /"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762208799-Lim19xB7tb7FXymGJLUT",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"Correctly estimate. For an all\u2011or\u2011nothing vaccine a fraction p is fully protected and the remainder have the same per\u2011exposure risk as unvaccinated. Thus incidence_vax = (1\u2212p)\u00b7incidence_unvax, IRR = 1\u2212p, and 1\u2212IRR = p, which equals the per\u2011exposure VE.\",\"answer_letter\":\"C\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Evaluating vaccine efficacy**\n\nI need to break down the question about all-or-nothing vaccines and their impact on the incidence rate ratio versus per-exposure vaccine efficacy. In this scenario, some individuals are fully protected while others are not. The per-exposure vaccine efficacy seems to be either 0 or 1. It\u2019s crucial to consider how this relates to the overall incidence seen in vaccinated groups based on the cumulative incidence among unvaccinated individuals and the fraction that remains unprotected. My goal is to think this through clearly.**Clarifying per-exposure VE**\n\nI'm considering how per-exposure vaccine efficacy (VE) is defined as the probability of infection among vaccinated versus unvaccinated individuals. For an all-or-nothing vaccine, the average probability reflects those who are fully protected and those who aren't. This leads to the per-exposure VE being equal to the fraction that is protected. The incidence rate ratio (IRR) calculated in trials helps correctly estimate the per-exposure VE, indicating that 1 - IRR equals the proportion protected. Ultimately, I conclude that for an all-or-nothing vaccine, the IRR does indeed correctly estimate the per-exposure VE.**Finalizing JSON response**\n\nI\u2019m putting together the final JSON structure, which will include a short explanation and the answer letter \"C.\" I need to clarify that in an all-or-nothing scenario, the vaccinated group consists of a protected fraction (p) with zero risk, while the remaining individuals have the same risk as the unvaccinated. Since the incidence ratio equals (1-p), I can deduce that 1 - IRR equals p, which represents the per-exposure VE. I want to keep this concise and clear!",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Evaluating vaccine efficacy**\n\nI need to break down the question about all-or-nothing vaccines and their impact on the incidence rate ratio versus per-exposure vaccine efficacy. In this scenario, some individuals are fully protected while others are not. The per-exposure vaccine efficacy seems to be either 0 or 1. It\u2019s crucial to consider how this relates to the overall incidence seen in vaccinated groups based on the cumulative incidence among unvaccinated individuals and the fraction that remains unprotected. My goal is to think this through clearly.**Clarifying per-exposure VE**\n\nI'm considering how per-exposure vaccine efficacy (VE) is defined as the probability of infection among vaccinated versus unvaccinated individuals. For an all-or-nothing vaccine, the average probability reflects those who are fully protected and those who aren't. This leads to the per-exposure VE being equal to the fraction that is protected. The incidence rate ratio (IRR) calculated in trials helps correctly estimate the per-exposure VE, indicating that 1 - IRR equals the proportion protected. Ultimately, I conclude that for an all-or-nothing vaccine, the IRR does indeed correctly estimate the per-exposure VE.**Finalizing JSON response**\n\nI\u2019m putting together the final JSON structure, which will include a short explanation and the answer letter \"C.\" I need to clarify that in an all-or-nothing scenario, the vaccinated group consists of a protected fraction (p) with zero risk, while the remaining individuals have the same risk as the unvaccinated. Since the incidence ratio equals (1-p), I can deduce that 1 - IRR equals p, which represents the per-exposure VE. I want to keep this concise and clear!",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCSwshIe0N6HSGS6XDOytdabLEUrLx19JXcQDPMnkbSQYZaJsFj8eJUHZNDXa8WV0A0yN6HJ4zmMSN1RVP3oPxfEBkDNXwdwwA9xYUZR06fGevZIlBqsI_IyfMUI8kNfHiakv4EoOocEzWagGaUttM_65DHTRksageosNdNVhV6E_hS1XWAPfFbzTb1vCZL611HUH5QyAR6F6fju6xsRzYXfmtdb1Zm2c0z1-Z2iGkw5aJ6m_7hYz3xZPR1qLXYn9LCHKcnopAJiJgk0G0CUOwl_0Kq6CA3FN06IWIJXx0zsstxegX_CizotodD7PdfilDcO-eTjdgOPHnf4pXU8Hh6kG3PgDgnf7JSg3yDpGyio-tlExyaUd5RjmYAJmeH3g0wAdKhcl_Z8iNZqH3IyFh4Z9Zo60ZYQddI5l4tYBl7MOcWFzqvBUXRTjtO778T4atTjKoUezPNCldSB8cDZTYvYabKqpqOF-fOtSB4tn-yPB3PIvpbeBkAq-SqeHK0gfuD7QuZp2ffW_5f3ezoxHBJykBYVIj4y9QFpRWo99SXWHK4PACM4w0Iam196nWaCGZfPHoIp1Vybc60urCqiW5sxa-b4bWPc9sczMa6mbjRsa_jgEY3hV5m91uT7WFMIcwJkWKb7gLP1K3b8XoFmMYqz60mmp5Wc3ZaZ5VF_9B9b2voJBHmUgnrjn0c-kAsyl1bc58LcHz0xBGLybhJiIRAnTMRil3Mw1ZGobcYJGDnQYeDn0aWwH-zVAJsIVuT4t6zTPvCUmv9sO38iTd05tdMVw7nBCCiIxp-xfM_OGHZqZw1chTd8cI7jAfUZgU_QBf5H7SfeAGPAv4QuSQ0TM9aSwJrtqoqQkQgiBrdTAG3typp5HoteZZ-WtFEZANtWquA_svw3TQKwdL-3vY_i6Df1kJQj3Rga65ax_1rGdBT9IYtC60EGRo8ECwVnSJx6NwoGCJoLz7kLTA3qdVkMhTCDFrMqL8FL2mi66UAg8Xb-5gh9hmnRLsDtBE_8D0-DsPALFTp6fL8srF5zjAuIoSPgckBNLtViUkry9RWZCVIGqo_AEW8hurHNXWp-ukcsSEm4G-WwsQBK29dl165ChErxDORx4J7D8idSkF39LjHXo3-4XNJdO_4XfOftTvyFMUC4Wa7HwpjJlE6iv5MlWPcktCGE-2RoIe4kWnY4_oMnSR9pnZdwBVgLEgEr-Ij8c4iYPMIEdElBRGqjevc-9NudwBG_H5o3s_1y8XowZqk3jWSoDBlx4y4D-gOBicKDMnCF3XZoJ1wKvQfy_Y14gI0Fa9sLIsEFEDlXaXOL-BeOCxZs4OOMWmpOf2TJBoO_qfhzNibIuQ5rLnz7kseIxJC4bYEW-Vc3MQ0OmuwQ2zgtfbrtNBXUAOu0wJg3pq-zZICVcf3GOc0N7NCXd2kSQF00AB8_wzws1SnxIjaW9juissTIxJ3XWRDPEkceHlqFsUbval10vZReTDSUyOMxBJutFiShzdFB6ccGAhAxYa36jGl7TPdcMgG_CJ43UqJf1qd8cdiWJUj6FypBXQKJJxlMM70ZC2TzG-fAIdP8c4Xl_xigl4-97tiqN_YkGxmh5lX788Gf6MhLrp31KBXr93e4GhCaBdNkgZ1ItLk0WADgTbmf9dWEOIQdmWlgpJdh1tSge4v0habazS8I7Phtwkvnw0xYt6sBHNWdO9JE9JofIJ_hSvJhg1DHgEyGEUgkBCzeq9KhIB1Zd74HCo6zCYf9CIqF3AsgzylhtKqWl4rrnsS9HCEqdvn0ajG95JTpq3Ls2bUc5Rfwnsf6VtHWOKvHd-6j0z8PY5Brkao2X1zsqZ4l870dqe5WuspWXwjojYibYr3qZ7FC6zfYXBxTJNPACk-DSPx7QygllvaSke8CmzgNhfmUfDigxUdp-Ezwox_tf9QgNwr6g9ZZRahzkBPqeZApoyDkn11vpI7h8UfqYoHZg4Tkpb1OzapuTTI0c82_uMa8CjYprTOguIl0C6k3dUVpgH16TP9SLPRlOhG2rw91cPKXGVHQcM1m61eqD2o9LY8hKeDHzVPCq98xHTXnBnu4AZbIwMGevvHHXcGW6QqXfkGFzdpaQQNnBjHpFd3pWbwz5NM8FTU2QJfghfcFUSBMsvHiHO0P-jPQEOIFV_C2EsIZbv8TiKTDq1uPR19DcNTaQIU5rm265zMxVfyosStZzzR6CUH5qE6GsmqOKA7AgFEsAcTFcKeeEWBVc5c4Im_rkKFUiCNh-kipWFAyZgUyJN1-3X_HjKLYV8zlGr7Zg5phk7IhG2A2-YHOKbWXUGr4CW-R0cy8f0n-l4gufrCA1i_iaZoG9oQiXOP9RRjfzvf3xAhDn2HhzfpzmR9e2GDonghiR_LxgFkpBhgZBzc_mdbyw0o9uYV79XBki2TxtBgwRmnyAUld0wExS8OGG1zphSW4wiXDPBeByg5Iwd8TmYqpZTgsgSAl8aA41ISSrnrgpN1dUFLe_8EW8h44sxnLE7etngnJKQhDXuSffqf1hEDzfx9sYuQlQB1iC0F3uqOKK711DJTjAUflbDS4FlIxGR2URKxstLxKZ556IRbLuFHCcVh6196QkHePxz_rTxIYLhfhIUvTs1_dfVNacvML0SKqfFPd2oQJK1bM-kRzOGi3iAd8VsbCB36-7SNzI2E_TJyNfvAL5TLBpH-33j0gox2pMtO1i0IKWDL88idbj0-3NuzIsho1duJAMJAKN13CATaMiN0wlLDHKXs9ZWGQpWl2RO2d0mCQYH-SWYLLvPVlrHNVKyq3MtO5oM_djvu8etDHztGTKGOheZBK8PIOdgq6iFqQtLKeZCDRSn2J_uh5Vov-B4Qx8s1e2ugR_nVWF2S-E9kVgT-Z9ZlKvno-LOT4CbppoHxwBNxtyZBPRwqWTQ4N1k_5WpxZQpb9_nJeACwm6z8lf_5w9x2MswY7XILmrfIg7d-2tVph-3pIQpAE7UCNzfAPNxlkOWN038uyGNNYKbl01FSKUL6TQqBSae8bcuLyuLBmuuPPsLLxF_k45bEQA3zG5icHfLQmboyCpuIfSZeMMIsP2LHhqtPpzBIz3zvnl89fgnbb6pf8uzMw1JVpXwBCWlIA_qehv8u1l4QrI7s8zewiqm4oBeVf_deyfdJPuc0XlMS_Yxd_89RsUZlsHqry-lA231JUsYLslSBeUKrAO4KPVCGYKxFbjf-zP2z1jw2UhnjjsqfRiPh3xXwyHchxaZ5IB-bPvJ4IsUqG-nRatbTpcmlptNMbhquUx8UMFqqQEj_JxIZgqhQKS9IB1XLAgLSS49tAT7XZsZrw_tzLj-ysSSf0CzsE8RabsF39-iqR8_iXvplWc_b-7wnSLy836QfBD9ZUVFyd8KCS7JsdWtcjRe_vZwCCg5dprjzI-A3Z4WTBMRguQVDLmaohoRo-K9ZrIre1SR0WwaIZX9A-6l5k7cOMtUC1REL_duSwDpqJHlObjn2u9b3mrcwZKkaiN6W0BiWk18RkZ8q9Rus9a0nvvaql5quuxHh5-AtimnYrVEa0tQDwE4jn9kw390c7PmHMCoBOmXan3mJ-a-emNwOaikT1YMDgywwNzzvZzeA7hffhyw8Lg_cD_eSlqBpNXOCBg8pVwHYAp8BtPSbJu_pAQxmu4bxQlhsWB9LhALiJqzTeQLo9sPCQ1A_wQUdeXpmf1MkBfY6EPjNFcCVsyAiu6zJ11ahgohCdoJuRRdOmCOLtrubwQWtP2_uZbhJJ4MxfNnPgnCFmQUAWWXPIfVtUV9NWSNcqpWdjjdRo0Vg8HgiVVWLZ3TOLjKDG9yTPvKMsucgDfxeIiy9Mof-BtcY4hcAeVjxP8en6xBduXmem_Ib4pnWNXkca112kthfl4AxOJT_oE6FESci9welvg0LI6ENvFxMFb42QWJP5Y99bveZ-JQLAf0TQielxXNEGyek8hjVE2h-nra0x83pvgHo2Z2bxQ",
                "id": "rs_0ee0953b1f750ab40169092c203ab48193a6ced582a39f7176",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762208799,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 606,
        "prompt_tokens": 101,
        "total_tokens": 707,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 512,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.00123725,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 2.525e-05,
          "upstream_inference_completions_cost": 0.001212
        }
      },
      "provider": "OpenAI"
    }
  }
]